As such, further characterisation of metabolic tissues and the associated β-AR subtypes mediating beneficial effects, as well as understanding the underlying mechanisms of side effects, could lead to the development of a novel class of β-AR agonists to combat obesity. This evidence concerns the gene ADRB2 and Obesity.